[Image from OrganOx]

[图片来自OrganOx]

OrganOx

奥加诺克斯

announced today that it completed a $142 million primary and secondary equity financing to accelerate growth opportunities.

今天宣布完成了 1.42 亿美元的初级和次级股权融资，以加速增长机会。

New investor HealthQuest Capital led the oversubscribed funding round. Existing investors BGF and Lauxera Capital Partners, with new investors Sofina, Soleus Capital and Avidity Partners participated, too. OrganOx’s investors also include the University of Oxford, Technikos, the Oxford Technology and Innovations Fund and Longwall Ventures..

新投资者HealthQuest Capital领投了超额认购的融资轮。现有投资者BGF和Lauxera Capital Partners，以及新投资者Sofina、Soleus Capital和Avidity Partners也参与其中。OrganOx的投资者还包括牛津大学、Technikos、牛津技术与创新基金和Longwall Ventures。

The funds aim to accelerate the company’s Metra platform in the large, high-growth organ technology global market.

这笔资金旨在加速该公司在大型高增长器官技术全球市场中的Metra平台。

Approved in the U.S., Europe, Canada and Australia, Metra is a normothermic machine perfusion (NMP) platform technology that has been utilized in over 5,000 liver transplants to date. The system keeps donor livers in a metabolically active state outside the body. This provides transplant teams the opportunity for functional assessment of the organ prior to transplant.

在美国、欧洲、加拿大和澳大利亚获批的Metra是一种常温机械灌注（NMP）平台技术，目前已应用于超过5000例肝脏移植。该系统使供体肝脏在体外保持代谢活跃状态，这为移植团队在移植前对器官进行功能评估提供了机会。

According to OrganOx, this leads to an increased number of organs available for transplant..

根据OrganOx的说法，这使得可供移植的器官数量增加。

OrganOx also has an investigational Metra system for kidney transplants under development. It plans to begin U.S. clinical trials for that platform “soon.” The company also expects to begin a first-in-human clinical study of Metra combined with eGenesis’ genetically engineered porcine livers to support patients with acute-on-chronic liver failure..

OrganOx公司还在开发一款用于肾脏移植的Metra系统，计划“很快”开始在美国进行该平台的临床试验。该公司还预计将开始一项首次人体临床研究，测试Metra与eGenesis公司的基因工程猪肝结合使用，以支持慢性肝衰竭急性加重患者。

CFO Steve Deitsch said in a news release that the latest investment supports the success of OrganOx’s current customers, expansion of its customer base and entry into new markets.

首席财务官史蒂夫·戴伊奇在新闻稿中表示，最新的投资支持了 OrganOx 当前客户的成功、客户群的扩展以及进入新市场。

“Organ disease and failure represent a large unmet need in healthcare, and we are excited to partner with HealthQuest Capital and the outstanding investor syndicate to work together to improve patient care and outcomes,” said Dr. Oern R. Stuge, OrganOx executive chair.

“器官疾病和衰竭代表了医疗保健领域的一大未满足需求，我们很高兴与HealthQuest Capital及杰出的投资者集团合作，共同努力改善患者护理和治疗效果，”OrganOx执行主席奥恩·R·斯图格博士表示。